Icanbelimod

N/A

Report date: 2023/06/02 09:58:32
NME

Base Information

Drug NameIcanbelimod
Drug Alias NameCBP-307
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSphingosine 1-Phosphate Receptor 1 modulators
TargetsSphingosine 1-Phosphate Receptor 1
Therapy Area/IndicationsPlaque psoriasisAutoimmune DiseasesDermatitis, Atopic +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkrainePakistan +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSuzhou Connect Biopharmaceuticals LtdConnect Biopharmaceuticals (Shanghai) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesConnect Biopharma Australia Pty LtdConnect Biopharmaceuticals (Shanghai) Co LtdSuzhou Connect Biopharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesDermatitis, AtopicColitis, Ulcerative
Inactive IndicationsPlaque psoriasisMultiple SclerosisCrohn Disease +[4] 

Other Information

ATC CodeN/A
Related LinksN/A